Apeloa Pharmaceutical Co.,Ltd (SHE:000739)

SHE:000739 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	11,489	11,957	11,440	10,506	8,910	7,852
Other Revenue	65.35	65.35	33.92	39.1	32.44	28.09
Revenue	11,554	12,022	11,474	10,545	8,943	7,880
Revenue Growth (YoY)	-0.28%	4.77%	8.81%	17.92%	13.49%	9.28%
Cost of Revenue	8,871	9,225	8,621	8,075	6,579	5,700
Gross Profit	2,683	2,796	2,853	2,470	2,364	2,179
Selling, General & Admin	1,089	1,121	1,125	985.33	906.43	957.56
Research & Development	658.22	641.47	624.87	532.92	446.22	350.06
Other Operating Expenses	9.68	12.76	23.3	31.76	33.05	38.83
Operating Expenses	1,735	1,785	1,775	1,563	1,405	1,356
Operating Income	948.48	1,012	1,078	906.8	959.39	823.59
Interest Expense	-28.46	-32.2	-43.77	-59.23	-35.72	-16.01
Interest & Investment Income	133.38	92.17	113.47	75.83	165.7	86.9
Currency Exchange Gain (Loss)	58.38	58.38	38.13	93.42	-23.09	-73.61
Other Non Operating Income (Expenses)	1.53	2.21	-23.85	-5.38	-3.58	-2.33
EBT Excluding Unusual Items	1,113	1,132	1,162	1,011	1,063	818.54
Gain (Loss) on Sale of Investments	-5.28	-10.13	-21.7	-82.61	-23.62	47.45
Gain (Loss) on Sale of Assets	0.21	0.28	1.33	1.37	0.28	8.52
Asset Writedown	3.81	-8.4	-	-4.67	-7.95	-10.2
Other Unusual Items	89.22	89.22	63.23	86.52	82.67	96.85
Pretax Income	1,201	1,203	1,205	1,012	1,114	961.15
Income Tax Expense	165.56	172.44	149.34	22.89	158.53	144.42
Earnings From Continuing Operations	1,036	1,031	1,055	989.17	955.55	816.73
Minority Interest in Earnings	0.24	0.27	0.03	0	-	-
Net Income	1,036	1,031	1,055	989.17	955.55	816.73
Net Income to Common	1,036	1,031	1,055	989.17	955.55	816.73
Net Income Growth	-2.25%	-2.30%	6.69%	3.52%	17.00%	47.58%
Shares Outstanding (Basic)	1,163	1,163	1,169	1,174	1,179	1,179
Shares Outstanding (Diluted)	1,163	1,163	1,169	1,174	1,179	1,179
Shares Change (YoY)	-0.54%	-0.52%	-0.40%	-0.38%	-0.00%	0.01%
EPS (Basic)	0.89	0.89	0.90	0.84	0.81	0.69
EPS (Diluted)	0.89	0.89	0.90	0.84	0.81	0.69
EPS Growth	-1.72%	-1.78%	7.12%	3.91%	17.00%	47.57%
Free Cash Flow	522.56	748.01	400.9	817	-90.18	742.41
Free Cash Flow Per Share	0.45	0.64	0.34	0.70	-0.08	0.63
Dividend Per Share	0.356	0.356	0.317	0.297	0.285	0.243
Dividend Growth	12.34%	12.34%	6.70%	4.21%	17.28%	47.27%
Gross Margin	23.22%	23.26%	24.86%	23.42%	26.43%	27.66%
Operating Margin	8.21%	8.42%	9.39%	8.60%	10.73%	10.45%
Profit Margin	8.97%	8.58%	9.20%	9.38%	10.69%	10.37%
Free Cash Flow Margin	4.52%	6.22%	3.49%	7.75%	-1.01%	9.42%
EBITDA	1,515	1,576	1,631	1,296	1,318	1,168
EBITDA Margin	13.11%	13.11%	14.21%	12.29%	14.74%	14.82%
D&A For EBITDA	566.7	563.97	553.06	389.43	358.64	344.06
EBIT	948.48	1,012	1,078	906.8	959.39	823.59
EBIT Margin	8.21%	8.42%	9.39%	8.60%	10.73%	10.45%
Effective Tax Rate	13.78%	14.33%	12.40%	2.26%	14.23%	15.03%
Revenue as Reported	11,554	12,022	11,474	10,545	8,943	7,880
Advertising Expenses	-	11.29	9.67	1.61	1.86	2.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.